MSTA, Mumps Skin Test Antigen, is indicated when detection of a delayed-hypersensitivity
(DH) reaction is desired.
MSTA has not been tested in persons immunized with live mumps vaccine; therefore,
its safety and efficacy in this population group has not been established.
MSTA is not indicated for the immunization, diagnosis, or treatment of mumps
virus infection, or determination of immune status to mumps virus.
DOSAGE AND ADMINISTRATION
Parenteral drug products should be inspected visually for extraneous particulate
matter and/or discoloration prior to administration. If these conditions exist,
Mumps Skin Test Antigen should not be administered.
SHAKE VIAL WELL before withdrawing each dose.
A separate, sterile syringe and needle or a sterile disposable unit should
be used for each patient to prevent transmission of hepatitis or other infectious
agents from person to person. Needles should not be recapped and should be disposed
of according to biohazard waste guidelines.
An injection of 0.1 mL of the antigen is made on the inner surface of the forearm.
Before injection, the skin over the site to be injected should be cleansed with
a suitable germicide. Care should be taken to inject the test antigen intradermally.
Interpretation of Reactions - The reaction should be examined in 48
to 72 hours. A mean diameter (i.e., the longest width plus the longest length,
divided by 2) of induration of 5 mm or more indicates a positive DH reaction
to the antigen. A negative reaction, if the test dose has been given correctly,
usually indicates either anergy or nonsensitivity. Pseudopositive reactions
may develop in persons highly sensitive to egg protein.
Vial, 1 mL (10 tests) - Product No. 49281-240-10
Store between 2°- 8°C (35°-46°F). DO NOT FREEZE.
Manufactured by: Aventis Pasteur Inc., Swiftwater PA 18370 USA.
Product information as of February 1997. FDA revision date: FEB 1997